BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...president and CEO of OncoMed Pharmaceuticals Inc., where Kapoun was SVP of translational medicine. Mereo merged with OncoMed...
BioCentury | Jun 4, 2020
Finance

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

...along with the biotech’s rare disease programs. Mereo gained the anti-TIGIT mAb when it acquired OncoMed Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...CFO and CBO at Chrono Therapeutics Inc., and Kapoun was SVP of translational medicine at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...Barnett as VP of clinical development. Li was VP of finance, principle financial/accounting officer at OncoMed Pharmaceuticals Inc....
BioCentury | Jun 17, 2019
Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

...acquisition by BMS. On Friday, the company declined its option to anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc....
BioCentury | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...SVP and general counsel of Tetraphase, has been promoted to CBO. Celgene declines option to OncoMed's...
...to license anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc. Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO), which acquired OncoMed...
...brexanolone (sage-547) AbCellera AbCellera Biologics Inc. Amgen Amgen Inc. Blueprint Medicines Blueprint Medicines Corp. Celgene Celgene Corp. Gilead Gilead Sciences Inc. Intra-Cellular Intra-Cellular Therapies Inc. Les Laboratoires Servier Mylan Mylan Inc. OncoMed OncoMed Pharmaceuticals Inc. Roche Sage...
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

...CBO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Li was VP of finance at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

...of breast and gynecologic cancer development. Prior to that, he was SVP and CMO at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

...Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus...
...with top-line data slated for 2H19. Celgene Corp. (NASDAQ:CELG) continues to hold an option for OncoMed's...
...OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Business: Musculoskeletal, Endocrine/Metabolic, Cancer Mark Zipkin BPS804, BPS-804 MPH-966, alvelestat (AZD9668) Mereo BioPharma Group plc OncoMed Pharmaceuticals Inc. Neutrophil...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...Ph I/II monotherapy (n=34) and combo with Keytruda (n=34) 3% mono;19% combo 32% mono;28% combo OncoMed Pharmaceuticals Inc....
...study and we have evidence that all of these steps are occurring,” van Elsas said. OncoMed Pharmaceuticals Inc....
...of immune activation, according to a press release announcing the results. Based on the data, OncoMed...
Items per page:
1 - 10 of 234
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...president and CEO of OncoMed Pharmaceuticals Inc., where Kapoun was SVP of translational medicine. Mereo merged with OncoMed...
BioCentury | Jun 4, 2020
Finance

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

...along with the biotech’s rare disease programs. Mereo gained the anti-TIGIT mAb when it acquired OncoMed Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...CFO and CBO at Chrono Therapeutics Inc., and Kapoun was SVP of translational medicine at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...Barnett as VP of clinical development. Li was VP of finance, principle financial/accounting officer at OncoMed Pharmaceuticals Inc....
BioCentury | Jun 17, 2019
Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

...acquisition by BMS. On Friday, the company declined its option to anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc....
BioCentury | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...SVP and general counsel of Tetraphase, has been promoted to CBO. Celgene declines option to OncoMed's...
...to license anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc. Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO), which acquired OncoMed...
...brexanolone (sage-547) AbCellera AbCellera Biologics Inc. Amgen Amgen Inc. Blueprint Medicines Blueprint Medicines Corp. Celgene Celgene Corp. Gilead Gilead Sciences Inc. Intra-Cellular Intra-Cellular Therapies Inc. Les Laboratoires Servier Mylan Mylan Inc. OncoMed OncoMed Pharmaceuticals Inc. Roche Sage...
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

...CBO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Li was VP of finance at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

...of breast and gynecologic cancer development. Prior to that, he was SVP and CMO at OncoMed Pharmaceuticals Inc....
BioCentury | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

...Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus...
...with top-line data slated for 2H19. Celgene Corp. (NASDAQ:CELG) continues to hold an option for OncoMed's...
...OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Business: Musculoskeletal, Endocrine/Metabolic, Cancer Mark Zipkin BPS804, BPS-804 MPH-966, alvelestat (AZD9668) Mereo BioPharma Group plc OncoMed Pharmaceuticals Inc. Neutrophil...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...Ph I/II monotherapy (n=34) and combo with Keytruda (n=34) 3% mono;19% combo 32% mono;28% combo OncoMed Pharmaceuticals Inc....
...study and we have evidence that all of these steps are occurring,” van Elsas said. OncoMed Pharmaceuticals Inc....
...of immune activation, according to a press release announcing the results. Based on the data, OncoMed...
Items per page:
1 - 10 of 234